Overall, TGFB1-mediated, EZH2-catalyzed SMAD3 K53/K333 methylation could function as a predictive marker of survival for patients with cancer and potentially serve as a therapeutic target for patients with metastatic cancer. The gene discussed is SMAD3; the disease is metastatic malignant neoplasm.